2022
Hypophosphatemia: A Practical Guide to Evaluation and Management
Tebben P. Hypophosphatemia: A Practical Guide to Evaluation and Management. Endocrine Practice 2022, 28: 1091-1099. PMID: 35940468, DOI: 10.1016/j.eprac.2022.07.005.Peer-Reviewed Original ResearchConceptsClinical manifestationsNormal phosphate homeostasisParathyroid hormoneFibroblast growth factorFunction of phosphateRange of symptomsCell membrane integrityEnzyme functionGrowth factorPhosphate balanceSkeletal mineralizationMembrane integrityChronic causesGastrointestinal tractPhosphate homeostasisDiverse rolesEnergy homeostasisHypophosphatemia
2004
Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism
Tebben P, Singh R, Clarke B, Kumar R. Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism. Mayo Clinic Proceedings 2004, 79: 1508-1513. PMID: 15595334, DOI: 10.4065/79.12.1508.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersDihydroxycholecalciferolsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHumansHyperparathyroidismMaleMiddle AgedParathyroid GlandsParathyroid HormoneParathyroidectomyPostoperative CarePreoperative CareProbabilityProspective StudiesSampling StudiesSensitivity and SpecificitySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsBone-specific alkaline phosphataseBone-specific alkaline phosphatase concentrationsFibroblast growth factor 23Primary hyperparathyroidismParathyroid hormoneSerum phosphorus concentrationFGF23 concentrationsSerum calciumSurgically treated primary hyperparathyroidismElevated serum calciumLow-normal rangeParathyroid hormone concentrationsAdult patientsPreoperative stateSerum phosphorusPostoperative stateHyperparathyroidismHealthy controlsFibroblast growth factorPatientsFGF23Growth factorSurgerySerumPhosphorus homeostasis